Nivolumab plus ipilimumab showed promising efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). The efficacy of the nivolumab plus ipilimumab combination regimen in NSCLC patients who relapse after durvalumab consolidation following concurrent chemoradiotherapy (CCRT) has not been determined. Between January 2021 and June 2022, clinical data were retrospectively extracted from the medical records of patients with NSCLC who received nivolumab plus ipilimumab after CCRT and durvalumab consolidation. A total of 30 patients were included in this analysis. The median number of durvalumab treatment cycles was 11. Median PFS and OS with nivolumab plus ipilimumab were 4.2 months (95% confidence interval [CI]: 0.7–7.7) and 18.5 months (95% CI: 3.5–33.5), respectively. The 6-month and 12-month PFS rates were 46.7% (95% CI: 28.8–64.5) and 36.4% (95% CI: 19.0–53.7). In multivariate analysis, a significant correlation was observed between a durvalumab treatment duration of 6 months or more and PFS (p= 0.04) as well as OS (p= 0.001). Grade 3 adverse events, including pneumonitis, dermatitis, and colitis, occurred in 10% of the patients. This study suggests that nivolumab plus ipilimumab is effective, especially in patients who have received durvalumab for 6 months or more, and tolerable for patients who relapsed after durvalumab following CCRT.
纳武利尤单抗联合伊匹木单抗在转移性非小细胞肺癌（NSCLC）患者中显示出良好的疗效。对于在同步放化疗（CCRT）后接受度伐利尤单抗巩固治疗期间复发的NSCLC患者，纳武利尤单抗联合伊匹木单抗方案的疗效尚未明确。本研究回顾性收集了2021年1月至2022年6月期间，在CCRT及度伐利尤单抗巩固治疗后接受纳武利尤单抗联合伊匹木单抗治疗的NSCLC患者的临床资料。共纳入30例患者进行分析。度伐利尤单抗治疗中位周期数为11个。纳武利尤单抗联合伊匹木单抗治疗的中位无进展生存期（PFS）为4.2个月（95%置信区间[CI]：0.7–7.7），中位总生存期（OS）为18.5个月（95% CI：3.5–33.5）。6个月和12个月PFS率分别为46.7%（95% CI：28.8–64.5）和36.4%（95% CI：19.0–53.7）。多变量分析显示，度伐利尤单抗治疗持续时间≥6个月与PFS（p=0.04）及OS（p=0.001）均存在显著相关性。10%的患者发生3级不良事件，包括肺炎、皮炎和结肠炎。本研究表明，对于CCRT后度伐利尤单抗治疗期间复发的患者，纳武利尤单抗联合伊匹木单抗具有疗效（尤其在度伐利尤单抗治疗持续时间≥6个月的患者中）且耐受性良好。
肿瘤(癌症)患者之家